top
Please input keywords
Order
*Country
日本
アメリカ
中国
オーストラリア
シンガポール
イギリス
フランス
ドイツ
スイス
イタリア
カナダ
韓国
オランダ
ベルギー
スウェーデン
その他
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hPD-L1/hCD40 mice
Strain Name
C57BL/6-Cd274tm1(CD274)Bcgen Cd40tm1(CD40)Bcgen/Bcgen
Common Name  B-hPD-L1/hCD40 mice
Background C57BL/6 Catalog number  120536
Related Genes 
CD274 (CD274 antigen)
CD40 (CD40 antigen)
NCBI Gene ID
60533,21939

Protein expression analysis


from clipboard


Strain specific CD40 and PD-L1 expression analysis in homozygous B-hPD-L1/hCD40 mice by flow cytometry. 

Splenocytes were collected from WT and homozygous B-hPD-L1/hCD40 (H/H) mice analyzed by flow cytometry with species-specific anti-PD-L1 antibody and anti-CD40 antibody. Mouse CD40 and PD-L1 were detected in WT. Human CD40 and PD-L1 were exclusively detected in H/H B-hPD-L1/hCD40 but not WT mice.


from clipboard


Strain specific CD40 and PD-L1 expression analysis in homozygous B-hPD-L1/hCD40 mice by flow cytometry. 

Splenocytes were collected from WT and homozygous B-hPD-L1/hCD40 (H/H) mice stimulated with anti-CD3ε in vivo (7.5 μg/mice), and analyzed by flow cytometry with species-specific anti-PD-L1 antibody. Mouse CD40 and PD-L1 were detected in WT. Human CD40 and PD-L1 were exclusively detected in H/H B-hPD-L1/hCD40 but not WT mice.


Combination therapy of PD-L1 mAb and CD40 mAb


from clipboard


Antitumor activity of anti-hCD40 antibody combined with anti-hPD-L1 antibody in B-hPD-L1/hCD40 mice. 

(A) Anti-hCD40 antibody combined with anti-hPD-L1 antibodies inhibited MC38-hPD-L1 tumor growth in B-hPD-L1/hCD40 mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-L1/hCD40 mice (female, 6-8 week-old, n=5). Mice were grouped when tumor volume reached approximately 80-120 mm3, at which time they were treated with Anti-hCD40 antibody combined with anti-hPD-L1 antibody and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-hCD40 antibody and anti-hPD-L1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-L1/hCD40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hCD40 antibodies and hPD-L1 antibodies . Statistical results showed significant weight loss in both G2 and G4 groups. As shown in panel B , anti-CD40 antibody significantly reduced body weight ,combination with PD-L1 antibody could relieve this symptom well.Values are expressed as mean ± SEM.